Introduction {#sec1}
============

Cellular identity can be guided by ectopic expression of master regulators ([@bib11]). Deriving induced pluripotent stem cells (iPSCs) through the activities of OCT3/4, SOX2, KLF4, and c-MYC ([@bib43]) provides a potent model in which to study the role of transcription factor coordination in driving somatic cells toward pluripotency. Early mechanistic studies using mouse embryonic fibroblasts (MEFs) were conducted through de novo introduction of viral vectors, each expressing an individual (monocistronic) reprogramming factor ([@bib3; @bib41]), where modulation of factor levels by viral titration led to altered reprogramming characteristics ([@bib50]). Monocistronic reprogramming allows for variation in copy number and integration site, and as a result, stoichiometry is inconsistent on a cell-to-cell level. Therefore, this method was succeeded by the development of polycistronic factor cassettes that can produce multiple proteins from one single transcript ([@bib17; @bib40]). Although such fixed polycistronic stoichiometry revealed the importance of relative factor ratios in determining the quality of reprogramming ([@bib5]), the principles that establish optimal stoichiometry remain undefined.

Studies of the mechanisms that underlie somatic cell reprogramming have revealed multi-step processes involving proliferation and cell-cell adhesion, along with molecular changes such as downregulation of lineage-specific genes and eventual upregulation of pluripotency markers ([@bib33]). Cell-surface markers were associated with reprogramming stages such as emergence of the embryonic stem cell (ESC) marker SSEA-1 (stage-specific embryonic antigen 1) ([@bib34; @bib41]). Secondary reprogramming systems ([@bib49]) helped define initiation, maturation, and stabilization as key stages in reprogramming toward pluripotency ([@bib8]). Proliferation, colony formation, and a mesenchymal-to-epithelial transition (MET) define the initiation phase ([@bib36]), while stabilization is characterized by transgene independence and activation of pluripotency reporters such as *Nanog* and *Dppa4* ([@bib10]). Thus, changes in global gene expression and epigenetics were associated with the progression of reprogramming through these stages ([@bib45]). However, discrepancies in reprogramming platforms influence reprogramming hallmarks, the severity of MET responses, lineage-specific gene repression and ectopic activation, the timing of cell-surface marker presentation, and the frequency of partial and complete reprogramming ([@bib10; @bib20; @bib26; @bib34; @bib36; @bib48]).

In order to clarify such method-dependent reprogramming hallmarks, we applied standard assays to compare polycistronic cassettes (constructed in-house or obtained from public resources) in a drug-inducible *piggyBac* (PB) transposon reprogramming system. The induced expression of various polycistronic cassettes in mouse fibroblasts evoked phenotypic and gene expression changes that we divided into two basic behavioral classes. An examination of individual factor sequences across the panel of polycistronic constructs revealed a re-occurring discrepancy in the *Klf4* cDNA defining two coding region length variants. Increased length at the KLF4 N terminus was associated with higher protein levels and thus altered relative factor stoichiometry, ultimately impacting both the initiation and stabilization phases of iPSC derivation. Here, we report the consequences of KLF4 N-terminal variation in mono- and polycistronic reprogramming experiments, and apply these findings to recognize and reconcile differences in reprogramming characteristics implied hitherto.

Results {#sec2}
=======

A Transposon System for Collating Polycistronic Reprogramming Cassettes {#sec2.1}
-----------------------------------------------------------------------

Reprogramming studies in mouse have made use of unique polycistronic factor arrangements and delivery vectors. For uniform evaluation of factor-order effects, we employed a fundamental reprogramming scheme based on factor transposition in MEFs ([@bib49]). The PB transposon vector (PB-TAC) employs doxycycline (dox)-responsive reprogramming cassette expression co-incidentally with a mCherry reporter ([Figure 1](#fig1){ref-type="fig"}A). ROSA-rtTA; Nanog-GFP MEFs combine the m2-rtTA transactivator ([@bib27]) with a Nanog-GFP reporter ([@bib28]). Thus, dox-responsive, PB-TAC-transgenic cells can be monitored throughout reprogramming initiation and maturation (day 2 \[d2\]--14) by mCherry fluorescence, while stabilization of pluripotency (d14--18) is indicated by activation of Nanog-GFP. Gain of factor independence through autonomous transgene silencing despite continued dox treatment is an established hallmark of the stabilization phase ([@bib10]), signaled here by a decrease in mCherry expression. For all polycistronic reprogramming cassettes tested, we routinely passaged populations on d8 and d18 using equal cell numbers without fractionation for extended culture and fluorescence-activated cell sorting (FACS) analysis. Dox-independent maintenance of iPSCs was verified by culture until d24, after which pluripotency was assayed by gene expression array and chimera contribution.

Initially, we used an alkaline phosphatase-positive (AP^+^) colony formation assay on d10 to compare various polycistronic cassettes with two previously published versions: OSKM ([@bib4]) and MKOS ([@bib17]). Across the range of vectors tested, OKMS, constructed through the combination of OSKM and pCX-OKS-2A ([@bib29]), displayed a reprogramming phenotype contradictory to OSKM and MKOS ([Figure 1](#fig1){ref-type="fig"}B and data not shown). Despite similar transfection efficiencies (∼3%--5% mCherry^+^ cells at d2 for both OSKM and OKMS), OKMS-induced AP^+^ colonies were clearly more abundant by d10, indicating that OKMS initiated somatic reprogramming more robustly than OSKM ([Figures 1](#fig1){ref-type="fig"}B and [S1](#app3){ref-type="sec"}A).

To evaluate iPSC stabilization, we assayed activation of the Nanog-GFP pluripotency reporter and silencing of factor-linked mCherry after d8 passage of OSKM and OKMS reprogramming cultures. Whole-well microscopic evaluation revealed that most OKMS-induced colonies were unable to activate Nanog-GFP by d18 ([Figure 1](#fig1){ref-type="fig"}C, left), whereas mCherry expression remained high. In contrast, OSKM cultures showed a majority of GFP^+^ colonies with silenced mCherry. FACS on d18 confirmed the proportions of reporter-positive cells ([Figure 1](#fig1){ref-type="fig"}C, right). Both the Total GFP^+^ and SSEA-1^+^ GFP^+^ fractions on d18 were consistently higher for OSKM reprogramming (mean 15.6% and 39.5%, respectively, versus 5.4% and 9.9% for OKMS; [Figure S1](#app3){ref-type="sec"}B). Conversely, overrepresentation of Total mCherry^+^ and SSEA-1^+^ mCherry^+^ populations was characteristic of OKMS (mean 53.1% and 58.8%, respectively, versus 21.0% and 27.0% for OSKM; [Figure S1](#app3){ref-type="sec"}B). GFP^+^ cells emerged only in the SSEA-1^+^ fraction (data not shown), and only in mCherry^low^ or mCherry^−^ cells, such that double-positive GFP^+^ mCherry^+^ cells were not observed under either condition ([Figure 1](#fig1){ref-type="fig"}C, right). Reporter ratios remained mostly unchanged after d18 passage and an additional 6 days of culture in dox (d24; [Figure S1](#app3){ref-type="sec"}C, left). Failure to activate Nanog-GFP was not associated exclusively with transgene interference, as dox withdrawal led to a complete loss of mCherry, but no increase in GFP for either the OSKM or OKMS populations ([Figures S1](#app3){ref-type="sec"}C and S1D). For both vectors, dox-independent, Nanog-GFP^+^ iPSC clones contributed to chimera formation and clustered with ESCs in microarray transcriptome analyses, validating pluripotency ([Figures S1](#app3){ref-type="sec"}E--S1G). These data suggest that OSKM more readily achieves stable reprogramming, whereas the majority of OKMS-induced cells remain in a transgene-dependent, partially reprogrammed state.

KLF4 Isoforms Underlie Phenotypic Differences in Polycistronic Cassette Reprogramming {#sec2.2}
-------------------------------------------------------------------------------------

We next sought to expose key differences underlying the distinct phenotypes observed for OSKM and OKMS, and initially examined the reprogramming factors at the DNA sequence level. Of particular interest, the 2A peptide cleavage site preceding *Klf4* in OSKM demarcated an ATG initiation codon that included an additional nine N-terminal amino acids (9aa) compared with that for OKMS ([Figure 1](#fig1){ref-type="fig"}D). When we examined public databases, we found that these two distinct *Klf4* isoforms correspond to open reading frames (ORFs) predicted from full-length cDNA cloning (GenBank accession numbers [U70662.1](ncbi-n:U70662.1){#intref0010} and [U20344.1](ncbi-n:U20344.1){#intref0015}) ([@bib9; @bib38]), anticipating proteins of 474aa and 483aa (GenBank accession numbers [AAC52939.1](ncbi-p:AAC52939.1){#intref0020} and [AAC04892.1](ncbi-p:AAC04892.1){#intref0025}; henceforth referred to as KLF4~S~ and KLF4~L~). To examine the effects of KLF4~S~ and KLF4~L~ on reprogramming while ruling out differences in factor order and 2A cleavage peptides, we introduced the N-terminal 9aa noted in OSKM (MRQPPGESD) directly into OKMS, producing OK^+9^MS (where K^+9^ is equivalent to KLF4~L~).

MEFs transposed with OK^+9^MS displayed a complete phenotypic switch. AP^+^ colony formation resembled that of OSKM ([Figures 1](#fig1){ref-type="fig"}E and [S1](#app3){ref-type="sec"}A). Whole-well imaging on d18 strikingly revealed that OK^+9^MS colonies were primarily GFP^+^ and there were few mCherry^+^ colonies ([Figure 1](#fig1){ref-type="fig"}F, left). The Total and SSEA-1^+^ fractions on d18 were predominantly GFP^+^ with extensive mCherry silencing, mirroring OSKM reprogramming behavior ([Figures 1](#fig1){ref-type="fig"}F, right, and [S1](#app3){ref-type="sec"}B). Dox-independent, GFP^+^ OK^+9^MS clones were chimera competent and shared a gene expression profile with OSKM and OKMS iPSCs, and ESCs ([Figures S1](#app3){ref-type="sec"}E--S1G).

Extended FACS analysis revealed the kinetics of mCherry^+^ cell expansion throughout the early phase (d2--8), equating OK^+9^MS with OSKM ([Figure 1](#fig1){ref-type="fig"}G). From our d8 FACS data, we found that a large proportion of OKMS mCherry^+^ cells were positive for SSEA-1. Therefore, we traced SSEA-1 dynamics from d2 to d8 (mCherry^+^ fraction; [Figure 1](#fig1){ref-type="fig"}H, left) and d10 to 18 post-passage (Total population; [Figure 1](#fig1){ref-type="fig"}H, right). Notably, only OKMS cultures were distinguished by rapid and robust SSEA-1 activation as early as d2 (29.4% versus 4.8% for OSKM, and 8.5% for OK^+9^MS), which continued through early reprogramming. For all constructs, SSEA-1^+^ cells remained mCherry^+^ through d8, at which point no Nanog-GFP activation could be detected. An examination of the increasing proportion of SSEA-1^+^ cells over d10--18 ([Figure 1](#fig1){ref-type="fig"}H, right) showed that activation of Nanog-GFP and coincident suppression of mCherry by OK^+9^MS were more consistent with OSKM, whereas for OKMS, both mCherry silencing and Nanog-GFP activation were less frequent ([Figures 1](#fig1){ref-type="fig"}I and 1J). Overall, these data indicate that elongation of *Klf4*~*S*~ to *Klf4*~*L*~ in OK^+9^MS subdues early reprogramming hallmarks but positively regulates stabilization of pluripotency.

Monocistronic Expression of *Klf4*~*S*~ or *Klf4*~*L*~ Does Not Differentially Influence Reprogramming {#sec2.3}
------------------------------------------------------------------------------------------------------

To determine whether the observed cassette-specific phenotypes were due to functional differences between KLF4~S~ and KLF4~L~, we performed a series of monocistronic *Klf4* expression experiments. We found that the transcriptome profiles of d6 mCherry^+^ cells arising from PB-TAC-*Klf4*~*S*~ or -*Klf4*~*L*~ MEF transfections were highly correlated (R = 0.999; [Figure S2](#app3){ref-type="sec"}A). Gene enrichment compared with mock-transfected MEFs revealed a common set of 476 genes enriched for Gene Ontology (GO) terms associated with extracellular matrix, skin development, and cell adhesion ([Figure S2](#app3){ref-type="sec"}B). Activation of a KLF4-responsive *Lefty1*-luciferase reporter ([@bib21]) was similar irrespective of the KLF4 variant ([Figure S2](#app3){ref-type="sec"}C), indicating that the capacity for regulation of this ESC promoter was unchanged. Moreover, both KLF4~S~ and KLF4~L~ could similarly rescue leukemia inhibitory factor (LIF)-independent culture of 1A2 Nanog-GFP reporter ESCs (data not shown). Thus, independent expression of either *Klf4* variant supported a preservation of functional capacity.

Considering the remarkable reprogramming phenotypes observed with polycistronic cassettes, we next addressed whether monocistronic expression of Klf4~S~ or Klf4~L~ in combination with polycistronic *Oct3/4*, *Sox2*, and *c-Myc* (OMS) had any detectable effect on iPSC derivation. OMS alone did not foster expansion of mCherry^+^ cells, which remained at a steady ∼6% through d18, nor did it activate SSEA-1 or Nanog-GFP expression (data not shown). Interestingly, expression of either *Klf4* variant in combination with OMS resulted in nearly indistinguishable reprogramming phenotypes using the assays outlined in [Figure 1](#fig1){ref-type="fig"} (see also [Figures 2](#fig2){ref-type="fig"}A, [S2](#app3){ref-type="sec"}D, and [S2](#app3){ref-type="sec"}E). These data demonstrate that the phenotypes associated with KLF4~S~ and KLF4~L~ arise mainly in the context of polycistronic factor linkage.

KLF4 Levels Are Diminished in OKMS and Rescued by N-Terminal Elongation {#sec2.4}
-----------------------------------------------------------------------

In order to rationalize the phenotypic differences observed between polycistronic cassettes, we evaluated transgene expression at the transcriptional and translational levels. Quantification of polycistronic mRNA revealed similar expression levels for OSKM and OKMS ([Figure S2](#app3){ref-type="sec"}F). Strikingly, western blotting on d2 revealed that dox-induced KLF4 was expressed at distinctly higher levels in OSKM compared with OKMS, whereas the levels of OCT3/4, SOX2, and c-MYC were generally comparable ([Figure 2](#fig2){ref-type="fig"}B). High KLF4 stoichiometry was also observed in MKOS, which, like OSKM, encodes KLF4~L~ ([Figure S2](#app3){ref-type="sec"}G). Consistent with the PB transposon experiments, MEFs from gene-targeted *Col1a1*-OSKM ([@bib27]) and -OKMS ESC chimeras faithfully reproduced cassette-specific protein levels (data not shown). Moreover, OK^+9^MS resulted in a marked increase in KLF4 levels compared with OKMS ([Figure S2](#app3){ref-type="sec"}H). Surprisingly, N-terminal elongation of KLF4~S~ in OKMS with a hemagglutinin (HA) epitope also rescued protein levels (OK~N-HA~MS; [Figure S2](#app3){ref-type="sec"}H) and even reprogramming phenotypes ([Figure S2](#app3){ref-type="sec"}I), whereas N-terminal HA extension of KLF4~L~ in OK^+9^MS did not result in any additional phenotypic change. Concordant with monocistronic phenotypes, transfection of PB-TAC-*Klf4*~*S*~ or -*Klf4*~*L*~ in MEFs produced comparable protein levels on d2 ([Figure S2](#app3){ref-type="sec"}J). These data indicate that the protein sequence at the KLF4 N terminus plays a role in specifically establishing polycistronic factor stoichiometry.

KLF4 Stoichiometry Regulates Reprogramming {#sec2.5}
------------------------------------------

To verify the reprogramming outcomes from adjusted factor stoichiometry, we supplemented OKMS with monocistronic factors in a PB-TAB transposon ([Figure 2](#fig2){ref-type="fig"}C). Supplementation of OKMS with *Klf4*~*S*~ or *Klf4*~*L*~ ([Figure S2](#app3){ref-type="sec"}J) markedly reduced d10 AP^+^ colony numbers ([Figures 2](#fig2){ref-type="fig"}D and 2G), reminiscent of the reduced colony formation efficiencies observed when OSKM or OK^+9^MS was employed. *Sox2*, but not *Oct3/4* or *c-Myc*, also had a significant effect on reducing colony formation frequencies compared with OKMS alone. Thus, both KLF4 isoforms modulated OKMS factor stoichiometry to subdue reprogramming initiation.

In the late phase of reprogramming, we gauged stabilization via mCherry silencing and Nanog-GFP activation ([Figures 2](#fig2){ref-type="fig"}E, 2F, and 2H). Supplementation of OKMS with either *Klf4*~*S*~ or *Klf4*~*L*~ was capable of activating Nanog-GFP with co-incident repression of mCherry on d18. Interestingly, although *Sox2* supplementation also showed a repressive effect on initiation, d18 mCherry^+^ and GFP^+^ proportions remained mostly unchanged, indicating that additional *Sox2* fails to rescue the OKMS stabilization phase. Likewise, *Oct3/4* and *c-Myc* failed to promote Nanog-GFP reporter activation or mCherry silencing. Thus, only *Klf4* variants were capable of augmenting the OKMS phenotype, implying a sensitivity of reprogramming pathways to KLF4 expression thresholds.

KLF4 Stoichiometry Is Reflected in Gene Expression Analyses {#sec2.6}
-----------------------------------------------------------

Global gene expression has been used to define reprogramming paths. In order to link gene expression to initial reprogramming behaviors, we subjected d6 mCherry^+^ cells from PB-TAC-OSKM, -OKMS, -OK^+9^MS, and -MKOS to microarray analysis ([Figures 3](#fig3){ref-type="fig"}A and 3B). Based on OSKM and OKMS GO term enrichment (data not shown) and results from previous reports, we established sample indexing criteria ([Figure 3](#fig3){ref-type="fig"}A, left). *Krt14* and *Krt17* (encoding structural proteins), as well as *Sfn* (a regulator of epithelial cell growth), are claimed to activate in reprogramming populations with preferred iPSC fate ([@bib26]). Expression of *Ocln* and *Cdh1* indicates MET responses ([@bib36]), while additional cell-surface changes are reflected by upregulation of *Cadm1* and *Fut9* (the fucosyltransferase responsible for producing SSEA-1). The developmental regulators *Tbx21* and *Bcl11a* (transiently upregulated non-ESC markers; [@bib34]) and the pre-iPSC marker *Nr0b1* ([@bib20]) show the extent of reprogramming. As early as d6, these ten marker genes were \>2-fold differentially expressed between OK^+9^MS (green series) and OKMS (red series; [Figure 3](#fig3){ref-type="fig"}A, left), and \<2-fold differentially expressed in a pairwise correlation of OSKM to OK^+9^MS (R = 0.993; [Figure 3](#fig3){ref-type="fig"}A, top right), certifying our indexing for further pairwise comparisons. Correlation and indexing of OSKM to OKMS verified the influence of KLF4 on early gene expression responses ([Figure 3](#fig3){ref-type="fig"}A, bottom right).

GO term analysis of commonly upregulated gene expression versus mock-transfected MEFs (PB-TAC-lacZ) was performed for cassettes containing *Klf4*~*L*~ and *Klf4*~*S*~ ([Figure 3](#fig3){ref-type="fig"}B and data not shown). For *Klf4*~*S*~ vectors (216 genes), only a few GO terms related to the biological processes "regulation of cell adhesion (laminins)" and "tissue morphogenesis," as well as the molecular function of "phospholipase C activity," were enriched with p values ≤ 1.0E-3 (data not shown). Nearly double the number of genes were activated by *Klf4*~*L*~ constructs (512 genes; [Figure 3](#fig3){ref-type="fig"}B; [Table S1](#mmc2){ref-type="supplementary-material"}). The common gene set for polycistronic *Klf4*~*L*~ constructs significantly enriched GO terms for cellular components of the "plasma membrane" and "cell-cell junction" (consistent with an expected MET response), as well as distinct enrichment for "keratinocyte differentiation" and "epidermal cell differentiation" biological processes (p = 2.3E-11 and 5.4E-11; [Figure 3](#fig3){ref-type="fig"}B, right) with Benjamini scores = 3.6E-8 and 4.1E-8, respectively. These data are consistent with monocistronic *Klf4* expression ([Figure S2](#app3){ref-type="sec"}B).

KLF4 Isoforms Divide Reprogramming Cassettes into Two Major Classes {#sec2.7}
-------------------------------------------------------------------

In order to more broadly understand the impact of KLF4-mediated reprogramming outcomes, we extended our analysis of publically available polycistronic constructs. DNA sequence surveys revealed that *Klf4*~*S*~ and *Klf4*~*L*~ reference cDNAs have been used interchangeably in the reprogramming field ([Table 1](#tbl1){ref-type="table"}). To confirm that public polycistronic vectors also display incongruous reprogramming behaviors, we selected MKOS ([@bib17]), STEMCCA ([@bib40]), EB-C5 ([@bib7]), and WTSI ([@bib52]), and applied our battery of phenotyping tests ([Figure S3](#app3){ref-type="sec"}). mCherry^+^ fractions and AP^+^ colony numbers varied among cassettes but were highest for OKMS and EB-C5 ([Figures S3](#app3){ref-type="sec"}A and S3C). Notably, all four *Klf4*~*S*~ cassettes (OKMS, STEMCCA, EB-C5, and WTSI) showed large proportions of mCherry^+^ SSEA-1^+^ cells on d8 (\>40%, compared with \<21% for *Klf4*~*L*~ cassettes OSKM, OK^+9^MS, and MKOS; [Figure S3](#app3){ref-type="sec"}B), a characteristic that was consistently associated with Klf4~S~ ([Figure 1](#fig1){ref-type="fig"}H). In accordance with *Klf4*~*L*~ construction and western blotting data ([Figure S2](#app3){ref-type="sec"}G), MKOS AP^+^ colony numbers were low on d10, and became mostly GFP^+^ mCherry^−^ colonies on d18 ([Figures S3](#app3){ref-type="sec"}D and S3E). On the other hand, the *Klf4*~*S*~ cassettes STEMCCA, EB-C5, and WTSI all perpetuated mCherry expression after d8 passage (74.8%, 80.9%, and 79.6%, respectively), and activated Nanog-GFP in \<3.0% of SSEA-1^+^ cells ([Figure S3](#app3){ref-type="sec"}E). Thus, the phenotypes elicited by these additional public cassettes predictably correlated reprogramming hallmarks with *Klf4* coding length.

Finally, gene indexing confirmed that MKOS (*Klf4*~*L*~) is distinct from STEMCCA (*Klf4*~*S*~; [Figure 3](#fig3){ref-type="fig"}C), substantiating the phenotypes reported in [Figure S3](#app3){ref-type="sec"}. Moreover, unsupervised clustering of d6 mCherry^+^ cell gene expression profiles from all eight constructs (PB-TAC-OSKM, -OKMS, -OK^+9^MS, -OK~N-HA~MS, -MKOS, -STEMCCA, -EB-C5, and -WTSI) generated a dendogram ([Figure 3](#fig3){ref-type="fig"}D) that distinctly bifurcated based on the *Klf4* variant employed in each vector ([Table 1](#tbl1){ref-type="table"}). Thus, early gene expression patterns disclosed the nature of cloned *Klf4*. Intriguingly, despite unrelated N-terminal sequence identity (yet predicted by phenotype), OK~N-HA~MS activated 463/512 (∼90%) of the core *Klf4*~*L*~ genes (data not shown) and clustered with *Klf4*~*L*~ vectors ([Figure 3](#fig3){ref-type="fig"}D). A standardized comparison of polycistronic reprogramming cassettes thus implicates KLF4 isoforms in differential modulation of the reprogramming transcriptome.

Discussion {#sec3}
==========

Principally, we have uncovered a fundamental characteristic of cloned *Klf4* that governs relative factor stoichiometry and reprogramming responses during mouse iPSC derivation with polycistronic constructs. At the root of our discovery lies the disparate coding prediction of full-length *Klf4* cDNA ([@bib9; @bib38]), resulting in two proteins with distinct N termini defined herein as KLF4~S~ and KLF4~L~. These two variants have seen unprejudiced use among vectors constructed for reprogramming ([Table 1](#tbl1){ref-type="table"} and associated references). OKMS (*Klf4*~*S*~) presented low KLF4 levels, which were restored along with *Klf4*~*L*~-related phenotypes by elongation of the KLF4~S~ N terminus by 9aa. Thus, OK^+9^MS excluded the influence of 2A peptide choice and factor order variation. Moreover, high KLF4-associated phenotypes were reproduced by supplementation of OKMS with either monocistronic *Klf4*~*S*~ or *Klf4*~*L*~, limiting the effect to a polycistronic context. Relative stoichiometry was explored in a recent study, and it was found that chemically controlled degradation of KLF4 resulted in premature termination of reprogramming ([@bib22]). Although precise factor titration and more direct biochemical assays may be required, our monocistronic reprogramming data argue against modification of an N-terminal functional domain, and rather support the idea that threshold levels of KLF4 are important for minimizing the occurrence of partial reprogramming.

Polycistronic cassettes encoding KLF4~S~ tend to permit rapid expansion of transgenic cells with robust SSEA-1 activation. Yet, this majority population is ultimately impeded in the acquisition and stabilization of pluripotency, as indicated by transgene dependence and high-level expression of markers associated with pre-iPSCs ([@bib20; @bib46]). Polycistronic reprogramming with *Klf4*~*L*~ or OKMS supplementation with *Klf~S/L~* improved reporter activation and dox independence. Nanog-GFP reporter activation is consistent with a central role for KLF4 in the core ESC pluripotency network, as ectopic expression of *Klf4* promotes epiblast stem cell conversion to ground-state pluripotency ([@bib12]) and prevents loss of pluripotency in the absence of LIF ([@bib23]). Transgene silencing is considered a hallmark of complete reprogramming ([@bib10]). How the silencing phenomenon is related to the acquisition of pluripotency, and whether it is coordinated directly or indirectly through KLF4 are issues of considerable interest.

Individual expression of either *Klf4*~*S*~ or *Klf4*~*L*~ in MEFs led to a potent epidermal gene response ([Figure S2](#app3){ref-type="sec"}B). Moreover, a similar response was noted as a common feature of d6 reprogramming populations induced with *Klf4*~*L*~ cassettes ([Figure 3](#fig3){ref-type="fig"}B). A retrospective examination of early reprogramming experiments recalls reports of epidermis-related gene activation ([@bib20]). *Klf4* knockout mice die postnatally from failed epidermal stratification ([@bib37]). Reciprocally, ectopic *Klf4* expression during embryogenesis results in premature barrier formation ([@bib16]). Therefore, it is pertinent that high KLF4 stoichiometry induces a cascade of epithelialization and expression of epidermis-associated genes such as *Krt6a*, *Krt17*, *Sprr1a*, *Cnfn*, and *Tgm1* during early reprogramming ([Figures 3](#fig3){ref-type="fig"}A and 3B; [Table S1](#mmc2){ref-type="supplementary-material"}). Interestingly, many of these genes are not expressed in ESCs, nor are they maintained in GFP^+^ iPSCs (data not shown), which brings into question their relevance in iPSC derivation. To address potential cellular heterogeneity, it will be important to link gene expression responses and reprogramming outcomes to specific subpopulations of cells. Thus, it remains to be determined whether the epidermal response elicited by excess KLF4 in the early phase directly contributes to high-fidelity reprogramming or to an alternate cell fate.

On the path toward induced pluripotency, investigators rely on gene expression patterns as milestones to gauge appropriate progression, and comparative analysis of publically available gene expression profiles is a common approach. Clearly, our data show that inconsistencies in the relative levels of KLF4 to OCT3/4, SOX2, and c-MYC can fundamentally confound comparative analysis. Application of monocistronic *Klf4*~*S*~ or *Klf4*~*L*~ leads to nearly indistinguishable reprogramming phenotypes. Thus, typical clonal isolation of fully reprogrammed iPSCs with monocistronic vectors, which is subject to phenotypic selection for appropriate factor expression levels, should be mostly unaffected. Mechanistic studies, on the other hand, are prone to transcriptional noise arising from variable factor expression between cells and among transgenes. We expect the KLF4 threshold effects observed herein to be pronounced when the relative factor stoichiometry is fixed, for polycistronic transfection or even in secondary reprogramming systems with pre-integrated transgenes ([@bib48; @bib49]). As such, we must be mindful that it is difficult to make direct comparisons across distinct reprogramming systems without first defining the inherent factor stoichiometry.

Experimental Procedures {#sec4}
=======================

Plasmid Construction {#sec4.1}
--------------------

The PB transposon-based PB-TAC expression vector (RDB13131) was generated by standard cloning (restriction digestion and ligation). PB-TAB vectors containing the four Yamanaka factors were generated by Gateway Cloning (Invitrogen) as described previously ([@bib49]). Monocistronic and polycistronic reprogramming cassettes constructed in-house or obtained from public resources ([Table 1](#tbl1){ref-type="table"}) were cloned into pDONR221 using PCR and attB/P Clonase (Invitrogen) or pENTR2B using standard restriction endonuclease cloning or InFusion (Takara Clontech). Note that the cassette from pPB-CAG.OSKMBpuΔtk ([@bib52]) is in the order O-S-K-M, similarly to OSKM ([@bib4]), and thus is referred to in the text as WTSI to avoid confusion. Modifications such as N-terminal extension and HA tagging were produced using InFusion or the Q5 Site-Directed Mutagenesis Kit (New England Biolabs). Sequences of the main Gateway Entry constructs (from *attL1* to *attL2*) were obtained using Sanger sequencing with Big Dye Terminator Ver3.1 chemistry (ABI) and assembled as contigs using Sequencher (GeneCodes). Complete details regarding the cloning procedures used, including InFusion amplification and sequencing primers, are available upon request.

MEF Isolation {#sec4.2}
-------------

Nanog-GFP ([@bib28]) transgenic reporter mice were maintained as homozygotes on a C57BL/6 background. For ROSA-rtTA; Nanog-GFP double transgenic MEFs, C57BL/6 homozygous *ROSA26*-rtTA females ([@bib27]) and inbred homozygous Nanog-GFP males were crossed. Mice bearing *Col1a1*-targeted OSKM and OKMS cassettes were generated as described previously ([@bib27]). MEFs were isolated from 12.5--13.5 days postcoitum transgenic embryos. Embryos were decapitated, eviscerated, and macerated, and then dissociated with 0.25% trypsin/EDTA at 37°C for 15 min and plated in DMEM containing 10% fetal bovine serum (FBS), penicillin-streptomycin, and L-glutamine. The presence of the desired transgenes and male gender were determined by PCR genotyping of residual embryonic tissues. Cells from male embryos were expanded 1:5 once and then frozen in liquid nitrogen. Cells for reprogramming were defrosted, counted, and plated for transfection without additional expansion. The genotyping primers are available upon request. Animal care and experiments using animal tissues were approved by the CiRA Animal Experiment Committee in accordance with Kyoto University guidelines.

PB Reprogramming and iPSC and ESC Culture {#sec4.3}
-----------------------------------------

MEFs were seeded in DMEM containing 10% FBS, penicillin-streptomycin, and L-glutamine on gelatinized (0.1%) 6-well dishes at a density of 1.0 × 10^5^ cells per 10 cm^2^. After a 24 hr culture, FugeneHD (Promega) was used to transfect cells with 500 ng of transposons (PB-TAC-OSKM, -OKMS, -OK^+9^MS, -MKOS, -STEMCCA, -EB-C5, -WTSI, -OK~N-HA~MS, -OK^+9^~N-HA~MS, and -lacZ) plus 1,000 ng of pCyL43 PB transposase plasmid at a Fugene/DNA ratio of 8 μL:2 μg. For top-up experiments, cells were co-transfected with 500 ng of PB-TAC-OKMS along with 500 ng of PB-TAB-*Oct3/*4, -*Sox2*, -*c-Myc*, -*Klf4*~*S*~, or -*Klf4*~*L*~, plus 1,000 ng of pCyL43 PB transposase plasmid. After 24 hr, the medium was replaced with ESC medium (DMEM containing 15% FBS, penicillin-streptomycin, GlutaMAX, β-mercaptoethanol, sodium-pyruvate, non-essential amino acids, LIF, and dox \[1 μg/mL\]). After transfection, cells were fed daily with dox-containing ESC medium. On d8, cells were trypsinized and re-seeded at 3.0 × 10^5^ cells per 10 cm^2^ on gelatin for late-stage analysis (until d18). For dox withdrawal, cells were again harvested on d18 and re-seeded at 3.0 × 10^5^ cells per 10 cm^2^ on gelatin in the presence or absence of dox, and analyzed on d24. For isolation of factor-independent iPSC clones, d18 cultures were reseeded on gelatin at limiting dilutions in the absence of dox, and colonies were picked on d24. Southern blot analysis using *Hind*III digestion and an mCherry probe identified genetically unique iPSC lines. Both dox-independent iPSCs and ESCs were maintained on mitomycin-c-inactivated DR4 MEF feeders and gelatin in ESC medium, with passage every 2--3 days. For all cells, total viable cell counts were performed using a TC10 Automated Cell Counter (Bio-Rad) with trypan blue exclusion.

HEK293T Cell Culture and PB Transfection {#sec4.4}
----------------------------------------

HEK293T cells were maintained in DMEM containing 10% FBS, penicillin-streptomycin, and L-glutamine. Then 3.0 × 10^5^ cells per 10 cm^2^ were transfected with 500 ng of transposons (PB-TAC-OK~N/C-HA~MS and -OK^+9^~N/C-HA~MS) plus 500 ng of PB-CAG-rtTA ([@bib49]) at a Fugene/DNA ratio of 8 μL:2 μg. After 24 hr, the culture medium was replaced with medium containing dox (1 μg/mL). After an additional 24 hr, transfected cells were harvested for western blot analysis.

Whole-Well Fluorescence Microscopy Imaging {#sec4.5}
------------------------------------------

Mouse fibroblasts were plated on standard tissue culture 6-well plastic plates (BD Falcon Labware). Images were acquired with a Nikon BioStation CT (Nikon) equipped with GFP and mCherry fluorescence filters and phase contrast using 2× lenses. The single-plane images of each channel were stitched automatically using the automated image analysis software CL-Quant 3.0 (Nikon).

AP Staining {#sec4.6}
-----------

Staining for AP activity was performed using the BCIP/NBT Alkaline Phosphatase Substrate Kit IV (SK-5400, Vector Laboratories) according to the manufacturer's instructions. Images were acquired with a color camera (Canon IXY Digital 900IS), and colony count analysis was performed using a custom CL-Quant 3.0 macro developed in cooperation with Nikon, with AP-stained, mock-transfected MEF plates used to establish background.

Flow Cytometry and Cell Sorting {#sec4.7}
-------------------------------

For FACS analysis, 3.0 × 10^5^ cells were stained on ice for 30 min with Alexa Fluor 647 conjugated SSEA-1 (480, sc-21702, Santa Cruz Biotechnology) antibody or the corresponding isotype-matched control, mouse IgM (1:50 dilution). Control staining with the appropriate isotype-matched control monoclonal antibodies (BD Biosciences) was included to establish thresholds for positive staining. Samples were analyzed using a BD LSRFortessa Cell Analyzer (BD Biosciences) with BD FACSDiva software (BD Biosciences). Flow cytometry data were analyzed and generated by FlowJo software (Tree Star). For cell sorting, the mCherry^+^ cell population was collected on a BD FACSAria II cell sorter (BD Biosciences).

Microarray Analysis {#sec4.8}
-------------------

Total RNA was prepared from harvested cells using the RNeasy Mini Kit (QIAGEN) according to the manufacturer's instructions. cDNA synthesis and transcriptional amplification were performed using 200 ng of total RNA with the Whole Transcript (WT) Expression Kit (Ambion/Affymetrix). Fragmented and biotin-labeled cDNA targets were hybridized to GeneChip Mouse Gene 1.0 ST arrays (Affymetrix) according to the manufacturer's protocols. Hybridized arrays were scanned using an Affymetrix GeneChip Scanner. Probe signal intensities were normalized with the RMA algorithm in GeneSpring. Quality, correlation, and cluster analyses were performed using GeneSpring GX software v12.1 (Agilent Technologies). GO term analysis was performed using the NIH DAVID Bioinformatics tool (<http://david.abcc.ncifcrf.gov/>). There is no straightforward way to derive gene numbers directly from probe sets, as the Affymetrix GeneChip Array platform makes use of redundant probes for a small subset of genes. Moreover, each expressed sequence tag (EST) is represented by a unique probe, despite the fact that multiple ESTs may be associated with a single gene transcript. For clarity, we refer to probe sets or entities as "genes" in the text.

Protein Analysis {#sec4.9}
----------------

For western analysis, we prepared total cell lysates by boiling 1 × 10^6^ cells for 10 min in SDS sample buffer (25 mM Tris (pH 6.8), 2% β-mercaptoethanol, 3% SDS, 0.05% bromophenol blue, and 5% glycerol). Lysates were resolved on SDS-polyacrylamide gels, and proteins were detected by western blotting using ECL Plus (Amersham Pharmacia). For western analysis, Sox-2 (Y-17, sc-17320, 1:1,000) and GKLF (H-180, sc-20691, 1:500) antibodies were used as described previously ([@bib17]). Mouse Anti-Oct-3/4 (40/Oct-3, 611203, 1:1,000) and c-Myc (9402, 1:1,000) antibodies were obtained from BD Biosciences and Cell Signaling, respectively. HA-probe (F-7, sc-7392, 1:200) and anti-actin (A2066, 1:5,000) antibodies were obtained from Santa Cruz Biotechnology and Sigma-Aldrich, respectively.

Material Distribution {#sec4.10}
---------------------

The PB-TAC reprogramming transposons are available through the RIKEN BRC DNA Bank (<http://dna.brc.riken.jp>) under accession numbers RDB13131--RDB13138. Gateway versions of the polycistronic reprogramming cassettes will be made available through AddGene (<http://www.addgene.org>). The PB transposase vector pCyL43 is available through the Wellcome Trust Sanger Center (<http://www.sanger.ac.uk/form/Sanger_CloneRequests>).
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====================
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Accession Numbers {#app1}
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![KLF4 Isoforms Underlie Phenotypic Differences in Reprogramming\
(A) Diagram of the PB reprogramming system and analysis steps. The PB-TAC transposon delivers inducible, reporter-linked (mCherry), polycistronic reprogramming cassettes (Poly) into ROSA-rtTA; Nanog-GFP MEFs (d-1). Cultures are induced with dox (d0, dox; filled arrows) and harvested on d8 for FACS and passage for late-stage analysis (d18). For AP staining, cultures are maintained without passage until d10. Full reprogramming and transgene independence is assessed by dox withdrawal from d18 to d24 (open arrows). Predicted expression periods for the mCherry and GFP reporters during iPSC derivation are shown with red and green gradated bars. Blue polygons represent PB 3′ (left) and 5′ (right) inverted terminal repeats. tetO, dox-responsive promoter; IRES, internal ribosome entry signal; pA, polyadenylation signal.\
(B) AP staining on d10 of OSKM and OKMS reprogramming cultures. Scale bar, 4,000 μm.\
(C) Day 18 fluorescence microscopy of entire wells (composite 10 × 10 fields) or selected insets (3 × 3 subfields) for mCherry^+^ and Nanog-GFP^+^ (left). Scale bars, 4,000 μm (full well) and 1,000 μm (inset). FACS analysis of mCherry and Nanog-GFP expression in d18 Total and SSEA-1^+^ populations (right).\
(D) Polycistronic cassette structure and sequence of the 2A-*Klf4* N-terminal cleavage junctions. Cloned cDNA is compared with murine *Klf4* GenBank mRNA sequences ([U20344.1](ncbi-n:U20344.1){#intref0060} and [U70662.1](ncbi-n:U70662.1){#intref0065}), indicating the position of the predicted initiation codons and amino acid translations. The N-terminal 9aa of [U20344.1](ncbi-n:U20344.1){#intref0070} were introduced into OKMS (*Klf4*~*S*~) to produce OK^+9^MS (*Klf4*~*L*~).\
(E and F) The OK^+9^MS construct was evaluated according to the assays outlined in (A)--(C). The results in (B), (C), (E), and (F) are representative of the results from at least three independent experiments (summarized in [Figures S1](#app3){ref-type="sec"}A and S1B).\
(G and H) Time-course analysis of mCherry^+^ cell expansion (G) and SSEA-1^+^ fractions (H) from OSKM, OKMS, and OK^+9^MS transfections cultured for the indicated number of days before (2, 4, 6, 8) and after (10, 14, and 18) passage. Means ± SE for three independent experiments.\
(I and J) Time-course analysis of mCherry silencing (left) and Nanog-GFP activation (right) in SSEA-1^+^ cells on the indicated number of days after day 8 passage (10, 14, and 18). Means ± SE for three independent experiments.\
See also [Figure S1](#app3){ref-type="sec"}.](gr1){#fig1}

![KLF4 Stoichiometry Affects Reprogramming Phenotypes\
(A) Reprogramming with polycistronic OMS + monocistronic *Klf4*~*S*~ or *Klf4*~*L*~ leads to nearly identical phenotypes, as analyzed by FACS for mCherry or SSEA-1 on d8 (left) and mCherry versus Nanog-GFP on d18 (right).\
(B) Western blot analysis of OCT3/4, SOX2, c-MYC, and KLF4 in OSKM or OKMS transfected MEFs cultured for 2 days with or without dox treatment. Actin was used as a loading control. Arrows show the two KLF4 isoforms. Note that SOX2 and c-MYC also differ in size based on their positions relative to 2A peptides in the polycistronic cassette ([Figure 1](#fig1){ref-type="fig"}D). Uncropped data are provided in [Figure S2](#app3){ref-type="sec"}G.\
(C--F) Supplementation of PB-TAC-OKMS was performed by co-transfection of additional factors in PB-TAB transposons. β-geo, lacZ-neo fusion gene.\
(D) AP staining on d10 after transfection with OKMS alone or in combination with *Oct3/4*, *Sox2*, *c-Myc*, *Klf4*~*S*~, or *Klf4*~*L*~. Scale bar, 4,000 μm.\
(E) Day 18 fluorescence microscopy of entire wells (composite 10 × 10 fields) or selected insets (3 × 3 subfields) for mCherry^+^ and Nanog-GFP^+^. Scale bars, 4,000 μm (full well) and 1,000 μm (inset).\
(F) FACS analysis of mCherry and Nanog-GFP fractions in the d18 SSEA-1^+^ population of the cultures shown in (E). The results in (D)--(F) are representative of the results of at least three independent experiments (summarized in G and H).\
(G) Quantification of the effects of factor supplementation on AP^+^ colony formation (D). Means ± SE for three independent experiments. n.s., not significant. ^∗^p \< 0.05, Student's t test.\
(H) Percentages of mCherry^+^ and Nanog-GFP^+^ populations from FACS analysis of factor supplementation (F). Means ± SE for three independent experiments. n.s., not significant. ^∗^p \< 0.05, Student's t test.\
See also [Figure S2](#app3){ref-type="sec"}.](gr2){#fig2}

![Gene Expression Patterns Reveal *Klf4* Variants\
(A) Pairwise comparison of global gene expression in mCherry-positive cells on d6 from OSKM, OKMS, and OK^+9^MS reprogramming. Diagonal lines indicate 2-fold changes in log~2~ signal intensity. Genes chosen for indexing are highlighted. Green: *Krt17*, triangle; *Sfn*, circle; *Ocln*, square; *Cdh1*, star; *Krt14*, inverted triangle. Red: *Fut9*, triangle; *Nr0b1*, circle; *Cadm1*, square; *Tbx21*, star; *Bcl11a*, inverted triangle.\
(B) Left: Venn diagram showing overlapping gene activation versus lacZ-MEFs in the *Klf4*~*L*~ cluster. Right: GO analysis of 512 shared d6 genes, arranged in order of p value and indicating the proportion of genes represented for each enriched GO term. Cutoff p = 1.0E-3.\
(C) Pairwise comparison of global gene expression in mCherry-positive cells on d6 from MKOS and STEMCCA reprogramming. Highlighted genes are those indicated in (A).\
(D) Dendogram resulting from unsupervised clustering of OSKM, OKMS, OK^+9^MS, OK~N-HA~MS, MKOS, STEMCCA, EB-C5, and WTSI mCherry d6 array samples. Segregation of the vectors based on the nature of the KLF4 N terminus is indicated.\
See also [Figure S3](#app3){ref-type="sec"} and [Table S1](#mmc2){ref-type="supplementary-material"}.](gr3){#fig3}

###### 

Survey of Publically Available Reprogramming Cassettes

  Source       Construct Data         Form[e](#tblfn5){ref-type="table-fn"}   Sequence Validation   Publication                                                                                                                            
  ------------ ---------------------- --------------------------------------- --------------------- -------------------------- ----------------------------------------------- --------------- ------ ----- ----- ----- --- --- ---------- ------------
  Addgene      stem cell; Klf4/KLF4   Shinya Yamanaka                         13370                 pMXs-Klf4                  Kruppel-like factor 4 (gut)                     *M. musculus*   mono   ●           −     ○   ○   16904174   [@bib43]
  Addgene      stem cell; Klf4/KLF4   Shinya Yamanaka                         15920                 pMXs-Klf4-IP               Kruppel-like factor 4 (gut)                     *M. musculus*   mono   ●           −     ○   ○   16904174   [@bib43]
  Addgene      Klf4/KLF4              Miguel Ramalho-Santos                   15950                 pLOVE-Klf4                 Kruppel-like factor 4                           *M. musculus*   mono   n/d   n/d   n/c   −   −   18371358   [@bib2]
  Addgene      stem cell; Klf4/KLF4   Shinya Yamanaka                         17219                 pMXs-hKLF4                 KLF4                                            *H. sapiens*    mono   ●           −     ○   ○   18035408   [@bib44]
  Addgene      stem cell; Klf4/KLF4   George Daley                            17227                 pMIG-hKLF4                 Kruppel-like factor 4 (gut)                     *H. sapiens*    mono   ●           ○     −   −   18157115   [@bib32]
  Addgene      stem cell; Klf4/KLF4   Kathrin Plath                           17967                 pMXs-hKLF4 (Plath)         Kruppel-like factor 4 (gut)                     *H. sapiens*    mono   ●           ○     ○   −   18287077   [@bib18]
  Addgene      stem cell; Klf4/KLF4   Konrad Hochedlinger                     19764                 pLV-tetO-Klf4              Klf4                                            *M. musculus*   mono         ●     n/c   ○   −   18371448   [@bib41]
  Addgene      stem cell; Klf4/KLF4   Konrad Hochedlinger                     19770                 pAd-Klf4                   Klf4                                            *M. musculus*   mono         ●     n/c   ○   −   18818365   [@bib42]
  Addgene      stem cell; Klf4/KLF4   Konrad Hochedlinger                     19777                 FU-tet-o-hKLF4             KLF4                                            *H. sapiens*    mono   ●           n/c   ○   −   18786420   [@bib19]
  Addgene      stem cell; Klf4/KLF4   Juan Belmonte                           20074                 pMSCV-Flag-hKlf4           hKlf4                                           *H. sapiens*    mono   ●           ○     −   −   18931654   [@bib1]
  Addgene      stem cell; Klf4/KLF4   Rudolf Jaenisch                         20322                 TetO-FUW-Klf4              Klf4                                            *M. musculus*   mono         ●     ○     ○   −   18371436   [@bib3]
  Addgene      stem cell; Klf4/KLF4   Rudolf Jaenisch                         20725                 FUW-tetO-hKLF4             KLF4                                            *H. sapiens*    mono         ●     ○     ○   −   18786421   [@bib14]
  Addgene      Klf4/KLF4              Rudolf Jaenisch                         20727                 FUW-tetO-lox-hKLF4         KLF4                                            *H. sapiens*    mono         ●     ○     ○   −   19269371   [@bib39]
  Addgene      Klf4/KLF4              Michel Sadelain                         23243                 pLM-mCherry-Klf4           mCherry_2A_KLF4                                 *H. sapiens*    mono   ●           n/c   ○   −   19549847   [@bib31]
  Addgene      Klf4/KLF4              Rudolf Jaenisch                         26274                 pBRPyCAG-fmKlf4-DsRed-Ip   Klf4                                            *M. musculus*   mono   ●           n/c   ○   −   20442331   [@bib13]
  Addgene      stem cell; Klf4/KLF4   Derrick Rossi                           26815                 pcDNA3.3_KLF4              5′UTR-KLF4-3′UTR                                *H. sapiens*    mono   ●           ○     −   −   20888316   [@bib47]
  Addgene      stem cell; Klf4/KLF4   Steven Dowdy                            36118                 pCX4-KLF4                  KLF4                                            *H. sapiens*    mono   n/d   n/d   n/c   −   −   22278060   [@bib15]
  Addgene      stem cell              Rudolf Jaenisch                         20331                 FUW-KO                     Klf4-F2A-Oct4                                   *M. musculus*   bi           ●     ○     ○   −   19109433   [@bib4]
  Addgene      stem cell              Rudolf Jaenisch                         20332                 FUW-KM                     Klf4-F2A-cMyc                                   *M. musculus*   bi           ●     ○     ○   −   19109433   [@bib4]
  Addgene      stem cell              James Thomson                           21164                 pSIN4-CMV-K2M              Klf4, cMyc                                      *H. sapiens*    bi     ●           n/c   ○   −   19325077   [@bib51]
  Addgene      stem cell              Shinya Yamanaka                         27078                 pCXLE-hSK                  SOX2, KLF4                                      *H. sapiens*    bi     ●           ○     ○   ○   21460823   [@bib24]
  Addgene      stem cell; Klf4/KLF4   Shinya Yamanaka                         41814                 pCE-hSK                    SOX2, KLF4                                      *H. sapiens*    bi     ●           ○     ○   ○   23193063   [@bib25]
  Addgene      Klf4/KLF4              Shinya Yamanaka                         19771                 pCX-OKS-2A                 Oct3/4-2A-Klf4-2A-Sox2                          *M. musculus*   poly   ●           n/c   ○   ○   18845712   [@bib29]
  Addgene      stem cell; Klf4/KLF4   Rudolf Jaenisch                         20321                 TetO-FUW-OSKM              Oct3/4-Sox2-Klf4-cMyc                           *M. musculus*   poly         ●     n/c   ○   ○   19109433   [@bib4]
  Addgene      stem cell; Klf4/KLF4   Rudolf Jaenisch                         20325                 FUW-SOKM                   Sox2-P2A-Oct4-T2A-Klf4-E2A-cMyc                 *M. musculus*   poly         ●     n/c   ○   −   19109433   [@bib4]
  Addgene      stem cell; Klf4/KLF4   Rudolf Jaenisch                         20327                 FUW-SOK                    Sox2-F2A-Oct4-T2A-Klf4                          *M. musculus*   poly         ●     n/c   ○   −   19109433   [@bib4]
  Addgene      stem cell              Rudolf Jaenisch                         20328                 FUW-OSKM                   Oct4-P2A-Sox2-T2A-Klf4-E2A-cMyc                 *M. musculus*   poly         ●     n/c   ○   −   19109433   [@bib4]
  Addgene      stem cell              Keisuke Kaji                            20865                 pCAGMKOSiE                 c-Myc-F2A-Klf4-T2A-Oct4-E2A-Sox2 (Alt name)     *M. musculus*   poly         ●     ○     ○   ○   19252477   [@bib17]
  Addgene      stem cell              Keisuke Kaji                            20866                 pCAG2LMKOSimO              c-Myc-F2A-Klf4-T2A-Oct4-E2A-Sox2-ires-mOrange   *M. musculus*   poly         ●     ○     ○   ○   19252477   [@bib17]
  Addgene      stem cell; Klf4/KLF4   James Thomson                           20923                 pEP4 E02S EM2K             Oct4 and Sox2; Myc and Klf4                     *H. sapiens*    poly   ●           n/c   ○   −   19325077   [@bib51]
  Addgene      stem cell              James Thomson                           20924                 pEP4 E02S CK2M EN2L        Oct4 and Sox2; Nanog and Lin28; Klf4 and Myc    *H. sapiens*    poly   ●           n/c   ○   −   19325077   [@bib51]
  Addgene      stem cell              James Thomson                           20925                 pEP4 E02S EN2K             Oct4 and Sox2; Nanog and Klf4                   *H. sapiens*    poly   ●           n/c   ○   −   19325077   [@bib51]
  Addgene      stem cell; Klf4/KLF4   James Thomson                           20927                 pEP4 E02S ET2K             Oct4 and Sox2; SV40LT and Klf4                  *H. sapiens*    poly   ●           n/c   ○   −   19325077   [@bib51]
  Addgene      stem cell              Tim Townes                              21627                 pKP332 (Lenti-OSK1)        hOCT4 - 2A - hSOX2 - 2A - hKLF4                 *H. sapiens*    poly   ●           ○     ○   −   19415770   [@bib6]
  Addgene      stem cell; Klf4/KLF4   Jose Cibelli                            24603                 OKSIM                      Oct4 KLF4 Sox2 c-Myc                            *H. sapiens*    poly   ●           n/c   ○   −   20030562   [@bib35]
  Addgene      −                      Michel Sadelain                         27512                 pLM-fSV2A                  OCT4_T2A_KLF4_P2A_cMYC_E2A_SOX2                 *H. sapiens*    poly   ●           −     ○   −   21151124   [@bib30]
  Addgene      stem cell              Linzhao Cheng                           28213                 pEB-C5                     Oct4, Sox2, Klf4, c-Myc, Lin28                  *M. musculus*   poly   ●           ○     ○   −   21243013   [@bib7]
  Kotton Lab   −                      Darrell Kotton, Gustavo Mostoslavsky    −                     pHAGE-Tet-STEMCCA          Oct3/4-Klf4-ires-Sox2-cMyc                      *M. musculus*   poly   ●           −     −   ○   19096035   [@bib40]
  WTSI         −                      Alan Bradley                            −                     pPB-CAG.OSKM-puΔtk         O-T2A-S-T2A-K-F2A-M                             *M. musculus*   poly   ●           −     ○   −   19337237   [@bib52]
  RIKEN BRC    −                      Knut Woltjen                            RDB13133              PB-TAC-OKMS                Oct3/4-Klf4-cMyc-Sox2                           *M. musculus*   poly   ●           −     −   ○              this study
  RIKEN BRC    −                      Knut Woltjen                            RDB13132              PB-TAC-OSKM                Oct3/4-Sox2-Klf4-cMyc (from 20321)              *M. musculus*   poly         ●     −     −   ○              this study
  RIKEN BRC    −                      Knut Woltjen                            RDB13135              PB-TAC-OK+9MS              Oct3/4-Klf4+9-cMyc-Sox2                         *M. musculus*   poly         ●     −     −   ○              this study
  RIKEN BRC    −                      Knut Woltjen                            RDB13136              PB-TAC-STEMCCA             Oct3/4-Klf4-ires-Sox2-cMyc (from [@bib40])      *M. musculus*   poly   ●           −     −   ○              this study
  RIKEN BRC    −                      Knut Woltjen                            RDB13134              PB-TAC-MKOS                c-Myc-F2A-Klf4-T2A-Oct4-E2A-Sox2 (from 20866)   *M. musculus*   poly         ●     −     −   ○              this study
  RIKEN BRC    −                      Knut Woltjen                            RDB13137              PB-TAC-EB-C5               Oct4, Sox2, Klf4, c-Myc, Lin28 (from 28213)     *M. musculus*   poly   ●           −     −   ○              this study
  RIKEN BRC    −                      Knut Woltjen                            RDB13138              PB-TAC-WTSI                O-T2A-S-T2A-K-F2A-M (from [@bib52])             *M. musculus*   poly   ●           −     −   ○              this study

WTSI, Wellcome Trust Sanger Institute; RIKEN BRC, RIKEN Bio Resource Center DNA Bank. Closed circles indicate the Klf4 variant, and open circles denote sequence validation steps for each construct. See also [Figures 3](#fig3){ref-type="fig"} and [S3](#app3){ref-type="sec"}.

Only vectors containing Klf4 are listed. Data from Addgene were current as of September 3, 2014. As Addgene is an independently curated and dynamically changing database, the authors do not warrant the accuracy or completeness of this resource beyond the date of data collection.

Addgene Collection lists can be found at <http://www.addgene.org/stemcell/> and <http://www.addgene.org/KLF/> or by browsing for Klf4 (gene 16600) or KLF4 (gene 9314).

Compared to mouse Klf4~L~, the human ORF is 87% and 90% similar at the nucleotide and amino acid levels, respectively, with 100% conservation across the first 35 amino acids. The effect of human Klf4~S/L~ on reprogramming was not tested in this study.

"Type" refers to the number of cistrons or ORFs in the construct.

Comparison of the ATG start site with [U70662.1](ncbi-geo:U70662.1){#intref0085} (Klf4~S~) and [U20344.1](ncbi-geo:U20344.1){#intref0090} (Klf4~L~) reference cDNAs. Note that for polycistronic vectors, this annotation does not take into account elongation by 2A peptides. n/d, form not determined by the available data.

Validation of Klf4 identity was from Addgene sequencing data. n/c, no coverage of the Klf4 start site, although available sequence confirmed the presence of Klf4.

Cassette sequences were verified empirically by the authors.

[^1]: Present address: Salk Institute for Biological Studies, La Jolla, CA 92037, USA
